AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1-28. (canceled).

29-30. (canceled).

31. (currently amended): The method of Claims ~~29~~34 or 35, wherein the heat shock polypeptide is derived from a bacterium.

32. (previously presented): The method of Claim 31, wherein the bacterium is a Mycobacterium.

33. (previously presented): The method of Claim 32, wherein the Mycobacterium is *Mycobacterium tuberculosis*.

34. (currently amended): A method of relieving pain comprising administering, to a subject in need thereof, a heat shock polypeptide or a nucleotide molecule encoding a heat shock polypeptide~~The method of any one of Claims 29 to 33~~,

wherein the heat shock polypeptide is a chaperonin,

wherein the nucleotide molecule comprises:

(i) at least one nucleotide sequence selected from the nucleotide sequence of SEQ ID NOs: 1, 3, and 5~~of Figure 1 and /or Figure 2 and/or Figure 3~~, or

(ii) a sequence which has ~~more than~~at least 66% identity to sequence (i)~~, or a sequence which hybridises to sequence (i) under conditions of 2 x SSC, 65°C (wherein SCC= 0.15M NaCl, 0.15M sodium citrate, pH 7.2), which~~

~~encodes a functionally equivalent polypeptide to the sequence encoded by the nucleotide sequence of Figure 1 and/or Figure 2 and/or Figure 3~~, or

(iii) a fragment of ~~sequence~~ sequence (i) or (ii) encoding a functionally equivalent polypeptide fragment wherein the functionally equivalent polypeptide fragment is from 3 to 400 residues in length.

35. (currently amended): A method of relieving pain comprising administering, to a subject in need thereof, a heat shock polypeptide or a nucleotide molecule encoding a heat shock polypeptide~~The method of any one of Claim 29 or 30~~,

wherein the heat shock polypeptide is a chaperonin,

wherein the polypeptide comprises:

(i) at least one amino acid sequence selected from the amino acid sequence of SEQ ID NOs:2, 4, and 6~~Figure 1 and/or Figure 2 and/or Figure 3~~, or

(ii) a sequence which has ~~more than~~at least 60% identity to sequence (i)~~ which provides a functionally equivalent polypeptide,~~ or

(iii) a functionally equivalent fragment of sequence (i) or (ii) wherein the functionally equivalent fragment is from 3 to 400 residues in length.

36. (canceled).

37. (previously presented): The method of Claim 36, wherein the functionally equivalent fragment is from 3 to 100 residues in length.

38. (previously presented): The method of Claim 34, wherein the nucleotide molecule encodes a functionally equivalent polypeptide fragment.

39. (currently amended): The method of ~~Claim 29~~Claim 34 or 35, wherein ~~the a~~said heat shock polypeptide or ~~a~~ said nucleotide molecule is administered in a composition comprising a pharmaceutically acceptable excipent, diluent or carrier.

40. (currently amended): The method of ~~Claim 29~~Claim 34 or 35, wherein ~~the a~~said heat shock polypeptide or ~~a~~ said nucleotide molecule is administered in a composition comprising at least one additive for assisting or augmenting the pain relief action ~~of~~ by the nucleotide molecule or polypeptide.

41. (previously presented): The method of Claim 40, wherein the additive is selected from at least one member of the group consisting of paracetamol, aspirin, ibuprofen, another non-steroidal anti-inflammatory drug (NSAID), a cylooxygenase-2-selective inhibitor (CSI), and an opiate.

42. (currently amended): The method of Claim 40, wherein the composition ~~is in a form which~~ provides prolonged or sustained pain relief.

43. (currently amended): The method of ~~Claim 29~~Claim 34 or 35, wherein said heat shock polypeptide or nucleotide molecule encoding a heat shock polypeptide are administered in single or divided doses at a daily dosage level of from 0.0001 to 100,000 mg.

44. (previously presented): The method of Claim 43, wherein said daily dosage level is from 0.0001 to 1000 mg.

45. (previously presented): The method of Claim 43, wherein the divided doses are administered between six and twelve hours apart.

46. (previously presented): The method of Claim 45, wherein the divided doses are administered between nine and twelve hours apart.

47. (previously presented): The method of Claim 43, wherein the divided doses are administered between twelve hours and twelve days apart.

48. (previously presented): The method of Claim 43, wherein the divided doses are administered between twelve days and six months apart.

49. (previously presented): The method of Claim 39, wherein the composition is formulated to permit administration by at least one route selected from the group consisting of intranasal, oral, parenteral, topical, ophthalmic, suppository, pessary and inhalation.

50. (previously presented): The method of Claim 49, wherein the composition is formulated to permit administration by inhalation.

51. (currently amended): The method of ~~Claim 29~~Claim 34 or 35, wherein the subject is a human or animal.

52. (previously presented): The method of Claim 51, wherein the subject is a human.

53. (currently amended): The method of ~~Claim 29~~Claim 34 or 35, wherein the pain is due to at least one member selected from the group consisting of backache, headache, toothache, earache, arthritis, gout, soft tissue trauma, ligament/tendon traumatic damage, a broken bone, cancer, post operative pain, menstrual pain, obstetric pain, renal tract pain, visceral pain, a burn, an abscess and an infection.